<qa>  What is the name of the first antipsychotic in the modern era?Affecting approximately 1 of any population worldwide, schizophrenia represents a major cause for morbidity and dysfunction for the afflicted and their loved ones, as well as a significant burden for the health care system and the society in general. Although antipsychotics are often remarkably effective in ameliorating schizophrenic symptoms and in enhancing social functioning, their use often is limited by their propensity to cause serious side effects that could further compromise patients health conditions. One such side effect is diabetes. Research publications from 1919, long before the advent of psychotropic medication, had showed schizophrenia might predispose individuals to diabetes.1 Following the introduction of chlorpromazine, the first antipsychotic in the modern era, a large number of case reports of antipsychotics-induced diabetes were reported. This complication seems more serious in the new type of antipsychotic, which is generally regarded as an atypical antipsychotic due to the lack of extrapyramidal reactions seen in schizophrenics treated with antipsychotics discovered previously. Several retrospective studies based on health services claim databases, strongly suggested that psychiatric patients exposed to atypical antipsychotics may be at a higher risk for developing diabetes. In addition, patients treated with these medications also appear to be at a higher risk for developing ketoacidosis. Risk factors included ethnicity African Americans, Asians, Hispanics and Native Americans, family history of diabetes and overweight or obesity. The association between these atypical antipsychotics and the onset of diabetes is further strengthened by observations of: 